Analyst interview with Ziccum CEO on significant milestones achieved

With two paid Evaluation agreements signed with world-leading mRNA partners, after having proven the LaminarPace technology for mRNA/LNP treatment, Q2 2023 was the most successful in Ziccum’s history. CEO Ann Gidner describes the company’s achievements and road ahead in the first of two CEO interviews.

Watch Ziccum CEO Ann Gidner in the first of two interviews with Eucaps analyst Jonathan Furelid HERE

Or visit Ziccum’s company page on Eucaps HERE.